INES Intelligent Investor Ethical Share ETF
- 3.250
- +0.040+1.25%
Jarden Research Adjusts Mineral Resources' Price Target to AU$48.50 From AU$47.20, Keeps at Sell
Morgan Stanley Downgrades Wesfarmers to Underweight From Equal Weight, Price Target Is AU$56.20
Jarden Adjusts Telstra Group Price Target to AU$4.00 From AU$4.40, Keeps at Buy
Goldman Sachs Downgrades Wesfarmers to Neutral From Buy, Price Target Is AU$68.80
Jarden Adjusts PSC Insurance Group Price Target to AU$6.19 From AU$4.80, Keeps at Neutral
Analysts Offer Insights on Healthcare Companies: Novartis AG (Six Swiss: CH:NOVN), Carl Zeiss Meditec (GB:0DHC) and Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD)
JPMorgan Downgrades Mineral Resources to Neutral From Overweight, Price Target Is AU$74
Morgan Stanley Adjusts CSL's Price Target to AU$310 From AU$318, Keeps at Overweight
Morgan Stanley Adjusts Resmed's Price Target to AU$31.80 From AU$28.60, Keeps at Overweight
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target Is AU$31
Jarden Adjusts Wesfarmers' Price Target to AU$58.60 From AU$48.60, Keeps at Neutral
Jarden Research CSL's Price Target to AU$296.02 From AU$298.57, Keeps at Overweight
Jarden Research Adjusts CSL's Price Target to AU$298.57 From AU$316.16, Keeps at Overweight
Jarden Research Adjusts Car Group's Price Target to AU$29 From AU$27.50, Keeps at Underweight
Morgan Stanley Upgrades Resmed to Overweight From Equalweight, Adjusts Price Target to AU$26 From AU$27.70
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Teladoc (TDOC) and Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) and Zur Rose Group AG (Six Swiss: CH:DOCM)